1. Scrip
  2. >>R&D

Epidemic Expert Kang On Tackling nCoV And Science As A Leveler

 
• By Anju Ghangurde

Gagandeep Kang of the Translational Health Science and Technology Institute and Coalition for Epidemic Preparedness Innovations talks to Scrip about early efforts to tackle nCoV-2019 and shares glimpses into her life journey in a wide-ranging interview.

Gagandeep Kang
Dr Gagandeep Kang

Gagandeep Kang, executive director of the Translational Health Science and Technology Institute (THSTI), an autonomous entity within India’s Department of Biotechnology, has pursued her career choices with steely resolve.

Her efforts over two decades to build a research program that conducted key studies to understand enteric infectious diseases in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.